Bordetella holmesii, a species closely related to B. pertussis, has been reported sporadically as a cause of whooping cough-like symptoms. To investigate whether B. pertussis-induced immunity is protective against infection with B. holmesii, we conducted an analysis using 11 human respiratory B. holmesii isolates collected during 2005-2009 from a highly B. pertussis-vaccinated population in Massachusetts. Neither whole-cell (wP) nor acellular (aP) B. pertussis vaccination conferred protection against these B. holmesii isolates in mice. Although T-cell responses induced by wP or aP cross-reacted with B. holmesii, vaccine-induced antibodies failed to effi ciently bind B. holmesii. B. holmesii-specifi c antibodies provided in addition to wP were suffi cient to rapidly reduce B. holmesii numbers in mouse lungs. Our fi ndings suggest the established presence of B. holmesii in Massachusetts and that failure to induce cross-reactive antibodies may explain poor vaccine-induced cross-protection.
an immunocompetent adolescent who had fever and pulmonary fi brosis (12) and from sputum of patients with respiratory failure (22) . Moreover, B. holmesii was isolated from nasopharyngeal specimens of previously healthy persons who had whooping cough-like symptoms, including paroxysms, whooping, or post-tussive vomiting (11, 21, 23) . Therefore, B. holmesii appears to be able to colonize the respiratory tract in the same manner as other Bordetella species. A case study in Japan also found epidemiologic links between 5 persons colonized with B. holmesii, which indicates the ability of this pathogen to transmit from person to person (6) .
In collaboration with the Massachusetts Department of Public Health (MDPH), we reviewed B. holmesii surveillance data collected in Massachusetts during [2005] [2006] [2007] [2008] [2009] . B. holmesii was isolated from several patients experiencing whooping cough-like symptoms. By using a murine infection model, we examined the effects of B. pertussis vaccination on B. holmesii infection susceptibility.
Materials and Methods

Identifi cation of B. holmesii Cases in Massachusetts
Culture-confi rmed B. holmesii cases identifi ed during 2005-2009 by the State Laboratory Institute at the MDPH were included in our analysis. According to MDPH guidelines, a nasopharyngeal swab was cultured if the patient was <11 years of age or had a cough for <14 days. For all other patients (>11 years of age and >14 days of cough), a serum test was performed. Details on culturing methods and Bordetella spp. identifi cation tests performed have been described (21) . A total of 41 B. holmesii infections were reported; the case records, including symptomology for 26 of these, are maintained in the Massachusetts Virtual Epidemiologic Network.
Bacterial Strains and Growth
B. pertussis strain 536 (24) and B. parapertussis strain CN2591 (25) have been described. B. holmesii strain P3421 was isolated in Massachusetts and used for animal experiments. Bacteria were maintained on Bordet-Gengou agar (Difco, Sparks, MD, USA) supplemented with 10% sheep's blood (Hema Resources, Aurora, OR, USA) without antimicrobial drugs (B. holmesii) or with 20 μg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA) (B. pertussis or B. parapertussis). Liquid cultures were grown overnight in Stainer-Scholte broth at 37°C to mid-log phase (26, 27) .
Phylogenetic Analysis
Phylogenetic analyses were performed on the basis of atpD, rpoB, tuf, and rnpB gene sequences as described (16 
Animal Experiments
All protocols were approved by Institutional Animal Care and Use Committee (IACUC). All animals were C57BL/6 mice and were handled in accordance with institutional guidelines (IACUC approval no. 31297). Animal experiments were performed as described, with 4 mice per group, and were performed in replicate (28) (29) (30) (31) (32) (33) . For vaccinations, sedated 4-6-week-old mice were vaccinated by intraperitoneal injection of 10 8 CFU of heat-inactivated (65°C for 30 min) bacteria in 200 μL of phosphate-buffered saline (PBS; Omnipur, Gibbstown, NJ, USA) for wholecell B. holmesii vaccine (wH) or wP B. pertussis vaccine; one fi fth human dose of Adacel (Sanofi -Pasteur, Swiftwater, PA, USA) (0.5 μg PT, 1 μg FHA, 0.6 μg pertactin, 5 μg fi mbriae 2 and 3 per mouse) with Imject Alum (Thermo Scientifi c) (aP); or only Imject Alum in 200 μL PBS on days 14 and 28 before challenge (28, 33) .
For challenge, 50 μL PBS containing 5 × 10 5 CFU of B. pertussis or B. parapertussis or 10 7 CFU of B. holmesii was added by pipetting onto the external nares of sedated mice (29) . A larger inoculum of B. holmesii was used to achieve reproducibility and detect B. holmesii from the respiratory tract at later time points, because it is cleared more rapidly from the lower respiratory tract than are B. pertussis or B. parapertussis. For adoptive transfer of serum antibodies, mice were vaccinated with the indicated bacteria on days 0 and 14, and serum samples were collected on day 28 from vaccinated or naive animals. Serum samples of 200 μL were intraperitoneally injected immediately before mice were inoculated with 5 × 10 6 CFU of B. holmesii (30, 32) . Bacterial numbers were quantifi ed as described (30) .
Splenocyte Restimulations
Splenocytes were isolated from vaccinated mice as described (31, 33) and stimulated with either media alone or media containing 10 7 CFU (multiplicities of infection of 5) of the indicated heat-killed bacteria (28, 31) . After 3 days, the supernatants were collected and analyzed for interferon (IFN) γ and interleukin-10 (IL-10) production by using ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
Titer ELISAs
Antibody titers were determined as described (34) (35) (36) . In brief, wP-or wH-induced/naive serum samples (1:200 dilution) or aP/adjuvant-induced serum samples (1:50 dilution) from each individual mouse were added to and serially diluted 1:2 across plates coated with heat-inactivated exponential-phase bacteria. After incubation, samples were probed with 1:4,000 dilution of goat anti-mouse Ig horseradish peroxidase-conjugated antibodies (Southern Biotech, Birmingham, AL, USA). Titers were determined by using the endpoint method (33) .
Western Blot Analysis
Lysates containing 10 7 CFU of indicated heat-killed bacteria were subjected to 10 % sodium dodecyl sulfatepolyacrylamide gel under denaturing conditions. Polyvinylidene fl uoride membranes (Millipore, Billerica, MA, USA) were probed overnight with either naive serum (1:100 dilution) or wH-(1:500 dilution), wP-(1:500 dilution), aP-(1:100 dilution) induced serum. A 1:10,000 dilution of goat anti-mouse Ig horseradish peroxidase-conjugated antibodies was used as the detector antibody (35, 37) . The membrane was visualized with ECL Western Blotting Detection Reagent (Pierce Biotechnology, Rockford, IL, USA).
Statistical Analysis
Mean ± SE values were determined for all appropriate data. Two-tailed, unpaired Student t tests, analysis of variance and Tukey's simultaneous test in Minitab (www. minitab.com) with similar signifi cance were used to determine statistical signifi cance between groups.
Results
B. holmesii Endemicity in Massachusetts
In 1999, Yih et al. reported an increase in culture-positive B. holmesii cases from 1995 to 1998 (0.2% to 0.6%) (23) . Here, collaborating with the same MDPH research team, we report the numbers of B. holmesii culture-positive nasopharyngeal specimens submitted to the MDPH during 2005-2009. Over these 5 years, B. holmesii was isolated from the nasopharyngeal swabs of 41 patients who had similar respiratory symptoms, which is 8 more total cases than observed by Yih et al. during 1994-1998 (33 total cases) (23) . At least 2 isolates were recovered each year, and 17 cases were identifi ed in 2006, the highest number observed ( Figure 1, panel A) . The rate of B. holmesii-positive nasopharyngeal swabs ranged from 0.1% to 0.4%, in line with previous results (Table) . Similar to observations made in prior years, 71% of cases occurred in persons 10-19 years of age ( Figure 1 , panel B), compared with >80% of cases during 1994-1998.
Symptom documentation was obtained for 26 of the 41 cases. All 26 of these patients had a cough; 17 (65%) had a paroxysmal cough, 6 (23%) had post-tussive vomiting, and 4 (15%) had an inspiratory whoop. Nineteen patients (73%) exhibited >1 of these classic symptoms of whooping cough and met the World Health Organization clinical case defi nition for pertussis (www.who.int/immunization_ monitoring/diseases/pertussis_surveillance/en/index.html). No data were collected regarding any previous underlying diseases or potential co-infections among these patients. Although we have no evidence that B. holmesii is the causative agent of these pertussis-like illness, these data suggest that B. holmesii is consistently present in the nasopharynx of a small number of patients who have respiratory infections in Massachusetts.
Phylogenetic Relationships among B. holmesii Isolates
To evaluate the phylogenetic relationships among B. holmesii isolates, an unweighted pair group method using average linkages tree was constructed on the basis of concatenated nucleotide sequences amplifi ed from regions of atpD, rpoB, tuf, and rnpB genes (16) . Twelve isolates were obtained from CDC (designated with the letter 'G'), while the remaining isolates were obtained from the MDPH. Consistent with previous fi ndings (16) , all the B. holmesii isolates tested were more closely related to B. hinzii and B. avium than to the classical bordetellae ( Figure 2 ). Al- Table) .
though single-nucleotide polymorphisms exist among B. holmesii isolates, pairwise comparisons among the 10 nasopharyngeal isolates from Massachusetts showed >99% sequence identity among 2,958 aligned bases, indicating their close relatedness. By comparison, the CDC isolates were more diverse, with the lowest percent sequence identity 97.5% between CDC strains G7851 and G4363. Moreover, B. holmesii isolates from blood and nasopharyngeal specimens do not cluster separately, which suggests that evolutionary relationship among B. holmesii isolates is not associated with the anatomic site of isolation.
B. holmesii Susceptibility to B. pertussis Vaccine-induced Immunity
Most records for the identifi ed B. holmesii culture-positive cases did not include information regarding vaccination history; however, 16 patients that were culture positive for B. holmesii received >3 doses of pertussis vaccine. The 2010 coverage among children in Massachusetts for DTaP (diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine) 4-dose vaccine was estimated to be >91%, ranking third among the 50 United States (www.cdc.gov/vaccines/ stats-surv/imz-coverage.htm). However, adolescents and adults have lower B. pertussis vaccine coverage and waning immunity against B. pertussis. More adolescents and adults compared with children were culture-positive for B. holmesii in Massachusetts, which suggests that B. pertussis vaccine may confer some level of protection against B. holmesii in recently vaccinated persons, similar to the cross-protection against B. bronchiseptica in a murine model of infection (38) . Although DTaP was not designed to prevent B. holmesii infections, it is critical to evaluate whether B. pertussis vaccines confer cross-protection against B. holmesii.
To test whether B. pertussis vaccines provide crossprotection against B. holmesii, we vaccinated C57BL/6 mice with wP or aP. These mice or vaccine-naive mice were then challenged with B. holmesii or B. pertussis and euthanized 3 days later. Because B. holmesii colonization effi ciency in the murine respiratory tract is low compared with the classical bordetellae, possibly because of the decreased attachment to mouse respiratory epithelium (A.T. Karanikas and E. T. Harvill, unpub. data), a higher challenge dose was used than for B. pertussis. wP vaccination reduced B. pertussis numbers in the lungs by >99.99% compared with naive mice; however, wP failed to reduce B. holmesii numbers (Figure 3, panel A) . In fact, wP vac- 
T-cell Responses to wH and wP/aP for B. holmesii
Because wP and aP fail to reduce B. holmesii numbers, we hypothesized that the pertussis vaccines may induce a different T-cell response than the wH vaccine does. To determine whether T-cell responses after vaccination are cross-reactive, splenocytes from naive or wH-, wP-, or aPvaccinated mice were stimulated with media or heat-killed B. pertussis, B. holmesii, or B. parapertussis for 72 hours. Cell culture supernatant cytokine concentrations of IFN-γ and IL-10, representing Th1 and Treg cytokines, respectively, were determined. wH vaccination did not induce IFN-γ and IL-10 production by splenocytes at greater levels than those produced by naive splenocytes (Figure 4) . However, splenocytes from wP-vaccinated mice produced high levels of IFN-γ and IL-10 on stimulation with heat-killed B. pertussis, B. parapertussis, or B. holmesii, which indicates that wP induces a strong cross-reactive T-cell response to B. holmesii. Although splenocytes from aP-vaccinated mice produced little IFN-γ, they produced ≈2,500 pg/mL IL-10 on stimulation with heat-killed B. pertussis, B. holmesii, or B. parapertussis, which indicates cross-reactive T-cell responses following aP vaccination. These data indicate that B. pertussis vaccines can induce cross-reactive T-cell responses to B. holmesii and thus do not explain the lack of cross-protection between these species. pertussis-specifi c Ig titers of wP-and aP-induced serum antibodies were 290,000 and 2,500, respectively wP-and aP-induced antibodies bind less well to B. parapertussis ( Figure 5, panel A) and confer little protection against B. parapertussis in vivo (33) . wP-or aP-induced antibodies bound even less well to B. holmesii. A similar trend was observed when live bacteria were used to coat the ELISA plates (data not shown), which rules out the possibility that heat inactivation selectively destroys cross-reactive antigens.
To compare the antigens recognized by serum samples from different groups, Western blot analyses were performed on B. pertussis, B. parapertussis, or B. holmesii lysates probed with naive serum or wH-, wP-, or aP-induced serum. wH-induced serum antibodies recognized B. holmesii antigens of various molecular masses but lacked crossrecognition of some higher molecular mass B. pertussis and B. parapertussis antigens ( Figure 5, panel B) . The wP-and aP-induced serum antibodies bound less effi ciently to B. parapertussis antigens than to B. pertussis antigens, consistent with published data (33) . Although wP-induced antibodies recognized some B. holmesii antigens, they lacked recognition of higher molecular mass (>60 kDa) B. holmesii antigens. aP-induced antibodies only poorly recognized a single B. holmesii antigen. Together, these data suggest that antibodies generated following B. pertussis vaccination do not effi ciently recognize B. holmesii antigens.
B. holmesii-specifi c Antibodies and wP-induced Immunity against B. holmesii.
On the basis of our data, we discerned that wP induces suffi cient T-cell responses but that antibody responses are not suffi cient to confer cross-protection against B. holmesii. If the lack of antibody cross-recognition is the only reason wP and aP vaccines are ineffective against B. holmesii infection, then adding B. holmesii-specifi c antibodies to wP should render the vaccination effective against B. holmesii.
To test this hypothesis, C57BL/6 mice were wP vaccinated or left untreated and later received either naive serum or wP-or wH-vaccinated mouse serum before B. holmesii challenge. B. holmesii lung colonization was determined 3 days postinoculation. Neither naive serum nor wP-induced serum reduced B. holmesii numbers, but vaccinated mice that received B. holmesii-immune serum had substantially lowered B. holmesii numbers in the lungs ( Figure 6 ). The fi nding indicates that the addition of B. holmesii-specifi c antibodies to wP increases its effi cacy against B. holmesii.
Discussion
The epidemiologic data collected by the MDPH suggest that B. holmesii is endemic in Massachusetts and is associated with classic whooping cough-like symptoms (Figure 1 ). Since the establishment of B. holmesii as a species in 1995 (10), infections have been sporadically reported worldwide (6) (7) (8) (9) 12, 13, 15, 17, 18, 20, 21, 23 ture, the only test that currently detects B. holmesii. Therefore, larger numbers of B. holmesii cases might be identifi ed if additional B. holmesii-specifi c serologic or PCR diagnostic tests are used.
When B. holmesii has been clinically identifi ed, several reports have demonstrated little heterogeneity among isolates on the basis of pulsed-fi eld gel electrophoresis banding patterns (21) and 16S rRNA heterogeneity (10, 17) . By using a sequence-based approach, Diavatopoulos et al. analyzed 7 B. holmesii isolates and observed only 1 nonsynonymous polymorphism among 3,666 bases (16) . Using a similar method, we further analyzed 20 isolates from CDC and 10 from MDPH and identifi ed 174 variable sites among the 2,958 aligned bases; this fi nding suggests more genetic variation among B. holmesii than previously recognized. Similar analyses on a wider range of B. pertussis, B. parapertussis, and B. holmesii isolates could better elucidate the evolutionary history among these human-adapted bordetellae.
Although vaccine studies are better completed in a natural host of the pathogen, the murine model of humanadapted bordetellae infection is well-established. B. pertussis and B. parapertussis murine infections mimic the course of infection and the immune responses in humans (30, 39, 40) , although an animal model of B. holmesii infection has not been previously described. Unlike the classic Bordetella species, B. holmesii colonizes the murine respiratory tract only when relatively large intranasal inoculums are delivered. This model may be improved, for example, by administering antimicrobial drugs or creating transgenic mice. In this study, reproducible colonization of the respiratory tract was achieved, and statistically signifi cant differences were observed after wH vaccination, which suggests that the mechanisms guiding protective immunity in this model can be used to investigate rapid immune-mediated interactions within the respiratory tract.
We determined that B. pertussis vaccines confer little, if any, protection against B. holmesii, even though 16S rRNA comparative analysis of B. holmesii and B. pertussis suggested that B. holmesii is closely related to B. pertussis. Furthermore, antibodies against B. pertussis pertactin, pertussis toxin, fi mbriae 2 and 3, adenylate cyclase toxin, and fi lamentous hemagglutinin recognized few, if any, proteins from multiple B. holmesii isolates (14) , which suggests that these proteins are absent from B. holmesii or are antigenically distinct from B. pertussis. Although vaccine-induced T-cell responses are cross-reactive to B. holmesii ( Figure  4) , B. pertussis vaccine-induced antibodies poorly bind B. holmesii ( Figure 5) . Furthermore, B. holmesii-specifi c, but not B. pertussis-specifi c, antibody administration effi ciently decreased B. holmesii numbers in the lungs of vaccinated mice (Figure 6 ), which suggests that the lack of cross-reactive antibody responses may result in poor cross-protection of B. pertussis vaccines against B. holmesii.
Our data indicate that B. holmesii is circulating in Massachusetts and that B. pertussis vaccination confers little protection against B. holmesii. Careful B. holmesii surveillance is required to better evaluate its prevalence and transmission. B. holmesii genome sequencing may identify novel virulence determinants to explain its emergence in the human population and guide effective vaccine design.
